Abstract
Optimal debulking followed by chemotherapy is the standard treatment of managing late-stage ovarian cancer, but chemoresistance is still a major problem. In this study, we compared expression profiles of primary tumor tissue from five long-term (>8 years) and five short-term (<2 years) ovarian cancer survivors and identified clusterin as one of the genes that were significantly up-regulated in short-term survivors. We then evaluated the prognostic significance of clusterin and its possible correlation with chemoresistance in ovarian cancer by immunohistostaining of clusterin in 62 tumor samples from patients with stage III, high-grade serous ovarian cancer. After adjusting for debulking status and age, Cox regression analyses showed that high levels of clusterin expression correlate with poor survival (hazard ratio, 1.07; 95% confidence interval, 1.002-1.443; P = .04). We also investigated clusterin in paclitaxel resistance by modulating the endogenous clusterin expression in ovarian cancer cells and treating the cells with purified clusterin. Results indicate that high-clusterin-expressing ovarian cancer cells are more resistant to paclitaxel. Moreover, exposing ovarian cancer cells to exogenous clusterin increases cells' resi...Continue Reading
Citations
Jul 7, 2011·Journal of Cellular Physiology·Sujit K BhutiaPaul B Fisher
Mar 5, 2013·PloS One·Cun WangYinkun Liu
Mar 19, 2013·International Journal of Molecular Sciences·Huijuan SongKwong-Kwok Wong
May 8, 2013·Molecular Human Reproduction·Jun ShaoDa-Jin Li
Nov 30, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ioannis A Voutsadakis
Nov 26, 2009·Oncogene·A E G LenferinkM D O'Connor-McCourt
Jun 16, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Celestine S TungKwong-Kwok Wong
Oct 2, 2009·Cancer Science·Li-Ru HeDan Xie
Oct 11, 2014·Expert Opinion on Drug Delivery·Khadija RhodaViness Pillay
Mar 26, 2016·Oncotarget·Jian WuDaiming Fan
Dec 10, 2009·The Journal of Biological Chemistry·Amy R Wyatt, Mark R Wilson
Apr 18, 2012·British Journal of Pharmacology·A Radziwon-BalickaM W Radomski
Aug 22, 2015·Journal of Ovarian Research·Yanxia FuGuofen Yang
Jan 29, 2013·Annual Review of Biochemistry·Amy R WyattMark R Wilson
Jun 28, 2014·International Journal of Oncology·L MagadouxV Laurens
May 5, 2017·Anti-cancer Drugs·Marilina García-ArandaMaximino Redondo
Aug 23, 2011·International Journal of Cancer. Journal International Du Cancer·Tibor FeketeBalázs Györffy
Sep 22, 2019·Cancers·Abdullah Hoter, Hassan Y Naim
Jul 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fred SaadUNKNOWN Canadian Uro-Oncology Group
Oct 12, 2011·Molecular Cancer Research : MCR·Masaki ShiotaMartin E Gleave
Jan 2, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Prakash Priyadarshi PraharajSujit Kumar Bhutia
May 28, 2020·Trends in Cancer·Emma C MaddenAfshin Samali
Feb 19, 2021·Journal of Biochemistry·Xueqin SunGuangying Cheng
Aug 12, 2009·Journal of Proteome Research·C Geeth GunawardanaEleftherios P Diamandis
Apr 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiaokun MaXiangyuan Wu